Introduction
Haemostatic defects in malignancy may be in haemostasis itself or fibrinolytic systems or in platelets. Disseminated intravascular coagulation (DIC) is one of the commonest haemostatic alterations observed in cancer patients.
DIC may be acute or chronic. Lung cancer of epithelial origin is a common cause of chronic DIC. Pathway remaining the same acute DIC occurs in an extrusive manner and chronic is slow and much less explosive. Lung cancer of epithelial origin is associated with chronic DIC.
Studies are performed with the aim of preventing any DIC-related catastrophe in the course of epithelial lung cancers and\or in their treatment. Mersky C, Johnson A.J, Kleiner P.J.
[1] evaluated the defibrination syndrome and noted the event of DIC is common in cancer and also in lung cancers.
As because smoking is very much preponderant in our country, lung cancer is increasing by leaps and bounds. It is most common cancer in male and third most cancer in females. As because our countrymen are less health conscious they usually present in later stages of the disease with much more associated complication and side effects making the treatment procedures all the more difficult.
So we have to throw light on these side effects also so that a better protocol can be formulated to alleviate symptoms as well as to help curative therapy. Disseminated Intravascular Coagulation or DIC of chronic nature is one of such common and much disturbing complication of epithelial origin carcinomas of lung. For this reason meticulous study and investigations are necessary for this kind of DIC.
As we all know this is an acquired type of DIC where tissue factors play the role of match-stick to activate the extrinsic pathway here vesicles and thromboplastin like cancer related products activates the extrinsic pathway initiates coagulation and gradually tilts the balance towards chronic DIC.
Works of Bick et al [2] and Saxena et al [3] laid down the criteria on chronic DIC and our present study also confirms that chronic DIC occurs in lung cancers of epithelial origin especially in advanced stages.
II. Materials And Methods
The following study was conducted in the department of Pathology (Haematology section) For the study case were selected from Department of Radiology and Chest Medicine after diagnosis but before treatment of malignancy and then blood samples are taken from patients and following tests were done. Total number of lung cancer patient in the study was 35. Controls were also 35, selected from healthy staffs and students of the medical college. Criteria for control were 1) non-smokers2) healthy and active3) no clinically proven disease of lung and liver, heart and haematopoetic system.
All technical parts of procedures are done as mentioned in Dacie, Lewis (Practical Haematology).
[4] 5cc of blood was drawn from each patient. For estimation of P.T & A.PT.T, 1.8 cc of blood was taken in a test tube containing 0.2 ml of citrate. Rest 3 ml blood was taken in EDTA vial. Two smears were made on glass slides by two drops of EDTA blood and stained by Wright`s stain and estimated for differential count of WBC, approximate total count of WBC which is also estimated by COULTER counter and Platelet count is done from stained blood smear and whenever necessary platelet count is done in Neubauer chamber using ammonium oxalate as diluents in usual method. Haemoglobin is estimated using cyanmethaemoglobin method with the help of Drabkin solution and colorimeter. P.T and A.PT.T-Platelet poor plasma is prepared from citrated blood (blood:citrate=9:1).
P.T. -Measures the clotting time of plasma in presence of thromboplastin and overall screens the extrinsic and common pathway. Commercially available rabbit brain extracts calibrated against international reference thromboplastin; water bath; and stopwatch is used.
A.P.T.T-Measures the clotting time of plasma after the activation of contact factor but without added tissue thromboplastin and so screens the intrinsic pathway. Kaolin; commercial phospholipid; 0.025mol/L Ca Cl2 are used. Paired results are taken with normal plasma taken as control and mean result is given in both PT & A.P.T.T.
FDP D`Dimer assay-XLFDP reagent (polystyrene latex particle, coated with mouse monoclonal Anti D` Dimer antibody DD3B6/22(Marketed by TULIP) can detect >=200ng/ml D` DIMER in plasma which is taken as positive. Positive &Negative controls, phosphate buffer diluents for semi quantitative assay and serial diluting plate, all are supplied with the kit. It is a semi quantitative assay. Plasma is serially diluted as1:2, 1:4, 1:8 and the like and the highest dilution for agglutination with reagent antibody are noted. Time for each agglutination reaction is fixed at3 minutes as per the literature with the kit. D` Dimer level=200xd where d=highest dilution of plasma for agglutination.
III. Results
It is evident that passive smoking must have a strong role in lung cancer of females and responsibility of their husband cannot be denied. (Table 2) .
From Table 3 it is evident that most cases belong to (51-60years) age group amounting to 40% and followed by (61-70 years) age group amounting to28.56%. Table 5 shows squamous cell carcinoma is the preponderant carcinoma in our country like India probably due to universality of smoking. Due to lack of health consciousness only stage III & IV cancers are available in our study. Only cancers of epithelial origin -sq. cell carcinoma, adenocarcinoma, bronchoalveolar carcinoma are taken for study.
It is evident from Table 6 that Platelet count is high in 18(51.43%) patients and normal in 17(48.57%) as in review article "haemostatic changes in malignancy-a review" by Saxena R et al [3] it is seen that malignancy chronic DIC shows normal to high platelet count. Platelet count at the range of1.5-4.5 lakhs/cubic mm was taken as normal range. Above 4.5 lakhs as high and below1.5 lakhs as low were considered.
Present study confirms the findings of Saxena R (Table 7) . Table 8 shows that in present study normal PT in most of the cases which is also in favour of chronic DIC. (normal range 11-16 seconds).
Present study shows in 19(54.28%) cases FDP D` Dimer is increased. (Table 9 ) It is surest marker of chronic DIC. Table 10 depicts that this study shows elevated D`Dimer level in 20% of stage-III and 60% in stage-IV consistent with the finding of Chopra et al (2001) [7] in which he observed chronic DIC in 31.25% cases of stage-III and 61.53% of stage-IV epithelial lung cancers. D Dimer` level above 200ng/ml is taken as positive or high as per literature in the kit.
This study shows 85.71% normal haemoglobin and decreased haemoglobin in14.29% cases. This has nothing to do with DIC as because decreased haemopoesis can occur with metastasis, circulating tumor product like TNF-alpha and they are sufficient to cause anemia in any type of malignancy (10gm% was taken as cut off point of normal haemoglobin for female and 12gm% for that of male) ( Table 11) .
As per Table 12 present study shows rise in TLC and neutrophilia as a result of inflammation and stimulation of bone marrow by products released by tumor cells. TLC more than 11000/cubic mm was taken as high count (as per Dacie Lewis) [4] . Percentage of neutrophil >80%was taken as high DC of neutrophil. Table 13 shows that in present study, out of 19 cases with raised FDP D` Dimer 11 cases that means 57.9% have high platelet count and out of total 35 studied cases 18 cases (51.43%) have high platelet count (vide Table 6 
IV. DISCUSSION
As per Wintrobes "Clinical Haematology"
[6] in contrast to inherited coagulation disorder acquired coagulation defects are multi factorial. Because of the compound nature of the haemostatic defect as in carcinomas the severity of bleeding correlates poorly with the results of the laboratory tests.
DIC can occur in-1) Carcinomas of lung, pancreas, breast etc; 2) Metastatic carcinoids, neuroblstomas, rhabdomyosarcomas; 3) Malignancies of haematopoetic system.
Mechanisms by which DIC is initiated-a) platelet adhesion& aggregation; b) activated extrinsic & intrinsic path. These exceed the normal compensatory process. In cancers tumor emboli and released tumor vesicles are thought to enter circulation and act as thromboplastin .These factors interacts with factor VII and activate the extrinsic pathway of coagulation. Tumor cell surface expression of tissue factors had been demonstrated (DovrakHF,Vandewalter et al).
[ 8] Results of quantitative studies demonstrate accelerated turnover of platelets, fibrinogen but plasma level of prothrombin which is consumed severely in vitro experiments is often normal in DIC especially in chronic DIC.
Intravascular fibrin formation-formation of fibrin in the form of small strands and micro clots is the immediate result of DIC. 1) Fibrinolysis-common finding in DIC; 2) Many of the thromboplastic substances released from the tumor mass also contain Plasminogen activators. Finally factor XIIa activates plasminogen by inter acting with normal proactivators and its kin in the system. Fibrinogen degradation product (FDP s)-the above mentioned processes degrade fibrinogen proteolytically.
Biologic effects of these products are -a) Acts as anti thrombin; b) Inhibit polymerization of fibrin; c) Produce structurally defective polymers; d) Impair platelet function; e) Impair RE system clearance function; f) Smaller peptides of 3000-4000 D inhibit smooth muscle activity.
Pathophysiology of chronic compensated DIC is same as acute but results from weak intermittently activated stimulus .In such cases destruction and production of coagulation factors are evenly balanced. Clinical features of chronic DIC-Recurrent episodes of epistaxis, extensive echymosis, migratory thrombophlebitis etc. are seen. It can be converted to acute DIC with dramatic suddenness following surgical trauma or pulmonary embolism. So chronic DIC is an intermediate step between acute DIC and hypercoagulable state. Some neurological symptoms may occur in chronic DIC.
A newly coined term is used by Joist et al In view of shortage of resources platelet count, PT, APTT, complete haemogram and FDP`D Dimer assay was taken as minimum criteria for assessment of DIC in this study.
Essential for treatment of low grade or chronic DIC is the treatment of underlying cause. 1) Supportive therapy is a must; 2) If thromboembolism continues anticoagulant therapy is indicated but aggressive anticoagulant therapy is contraindicated; 3) Therapy must be individualized depending on age site, stage of cancer severity of haemorrhage, infection and chemotherapy; 4) Surgery and radiotherapy may tilt the balance towards acute DIC and trigger severe bleeding and thrombosis.
Considering the above mentioned modalities proper study of incidence of chronic DIC in epithelial lung cancers is that much important. 
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